According to the SmPC, these include: Nausea (very common, affecting more than 1 in 10 people) Diarrhoea (very common) Decreased appetite (common, affecting up to 1 in 10 people) Vomiting (common) Abdominal pain (common) Abdominal distension (common) Constipation (common) Dyspepsia (common) Flatulence (common) These gastrointestinal effects typically occur during the initial weeks of treatment and often diminish as the body adjusts to the medication
Robinson, G
GLP-1 receptor agonists are medications that mimic the action of the hormone glucagon-like peptide-1, enhancing insulin secretion, inhibiting glucagon release, slowing gastric emptying, and promoting satiety
doi: 10.1210/en.2009-0803 114 NavarroVMFernndez-FernndezRCastellanoJMRoaJMayenABarreiroMLet al
The current protocol (CLI 00125 version 8.0) incorporates revisions to improve comprehension and a reduction in the total number of transfused subjects from 600 to 292 subjects following a blinded interim analysis that confirmed the overall incidence of the primary endpoint and the power of the study
At Yep Ads, were connected with leading telehealth providers, subscription programs, and health brands running high-value campaigns right now
